Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
出版年份 2020 全文链接
标题
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-04-23
DOI
10.1038/s41375-020-0828-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inter-species variation in monovalent anion substrate selectivity and inhibitor sensitivity in the sodium iodide symporter (NIS)
- (2020) Susanna C. Concilio et al. PLoS One
- Armed oncolytic viruses: A kick-start for anti-tumor immunity
- (2018) J.F. de Graaf et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Stefania Oliva et al. Frontiers in Immunology
- Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
- (2017) A Dispenzieri et al. LEUKEMIA
- High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
- (2017) A Miller et al. Blood Cancer Journal
- Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.
- (2017) Tiphaine Delaunay et al. OncoImmunology
- Dendritic Cell Therapies for Hematologic Malignancies
- (2017) Matthew Weinstock et al. Molecular Therapy-Methods & Clinical Development
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
- (2015) H Suen et al. LEUKEMIA
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Human Tumor Antigens and Cancer Immunotherapy
- (2015) Nathalie Vigneron Biomed Research International
- Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
- (2014) E. Galanis et al. CANCER RESEARCH
- Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
- (2014) Stephen J. Russell et al. MAYO CLINIC PROCEEDINGS
- Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients
- (2013) Willemijn Hobo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
- (2013) Massimo Martino et al. Clinical Lymphoma Myeloma & Leukemia
- Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
- (2013) Toshihiro Miyamoto et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- G-Protein-Coupled Receptor Kinase-5 Mediates Inflammation but Does Not Regulate Cellular Infiltration or Bacterial Load in a Polymicrobial Sepsis Model in Mice
- (2013) Nandakumar Packiriswamy et al. Journal of Innate Immunity
- Oncolytic Viruses for Induction of Anti-Tumor Immunity
- (2012) Alex W. Tong et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter for Squamous Cell Cancer of the Head and Neck Radiovirotherapy
- (2011) Hongtao Li et al. HUMAN GENE THERAPY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma
- (2009) D. Atanackovic et al. CLINICAL CANCER RESEARCH
- Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
- (2008) C L White et al. GENE THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started